Trials / Completed
CompletedNCT04501666
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 286 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nemolizumab 30 mg | Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection. |
| DRUG | Placebo | Participants received matching placebo as SC injection. |
Timeline
- Start date
- 2020-09-11
- Primary completion
- 2022-11-11
- Completion
- 2023-02-21
- First posted
- 2020-08-06
- Last updated
- 2024-07-10
- Results posted
- 2024-07-10
Locations
100 sites across 10 countries: United States, Austria, Canada, Denmark, Germany, Hungary, Italy, Poland, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04501666. Inclusion in this directory is not an endorsement.